Clinical Trials | November 27, 2025
Otsuka files FDA application for first-in-class ADHD drug
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Jaypirca is making waves in the fight against B-cell malignancies
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
The proposed transaction will be effected as a share swap
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
Subscribe To Our Newsletter & Stay Updated
